Recruiting

Testing a new eye injection to treat age-related macular degeneration

Plain-English translation of NCT05803785 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage safety trial of , a new medication delivered directly into the eye as an injection. The study is testing whether this medication is safe and well-tolerated in patients with neovascular age-related macular degeneration (a serious eye condition that causes vision loss). Researchers will also look for early signs that the medication might help improve or stabilize vision.

Many patients with this type of macular degeneration stop responding well to currently available anti-VEGF medications, leaving them with limited treatment options. This trial is exploring whether this new medication might help patients whose disease is not well-controlled with existing therapies.

Do you qualify?

You likely qualify if…

you are at least 50 years old
you have been diagnosed with neovascular age-related macular degeneration with active abnormal blood vessel growth confirmed by imaging
you have already received at least two doses of standard anti-VEGF eye injections but your condition hasn't improved as expected
your vision is between certain measurable levels (roughly between 20/40 and 20/400 on a standard eye chart)
you can stop other anti-VEGF medications for at least six weeks before starting this study
you are willing to provide informed consent and complete all required study visits and procedures

You likely don't qualify if…

you have received steroid injections into or near your eye within the past 90 days
you have glaucoma that is not well-controlled or have had glaucoma surgery
you have other serious eye diseases besides macular degeneration, such as diabetic retinopathy or eye infections
you have very advanced macular degeneration with severe damage to the central retina, making vision improvement unlikely
you have had eye surgery or certain types of laser treatment within the past 90 days, or have a history of herpes infection in your eye

What participation looks like

You will receive a single injection of the medication directly into your eye during the study. The study uses three groups that receive different doses, starting with the lowest dose and moving to higher doses as safety is confirmed. You'll attend multiple follow-up visits where your eye will be examined with imaging tests (like OCT scans and eye photographs) to check for any side effects and to see if your vision changes. The entire study will track your safety and vision over several months following your injection.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(2 sites)

Australia

Benobio Investigational site, Sydney, New South Wales

Sydney Hospital, Sydney